First report ofFIP1L1-PDGFRα-positive eosinophilic granulomatosis with polyangiitis : Fig. 1

Is there a role for imatinib mesylate in the treatment of eosinophilic granulomatosis with polyangiitis?

(2015) Gian Luca Erre et al.   JOINT BONE SPINE

Diagnosis and classification of eosinophilic granulomatosis with polyangiitis (formerly named Churg–Strauss syndrome)

(2014) Luc Mouthon et al.   JOURNAL OF AUTOIMMUNITY

Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): state of the art

(2013) A. Vaglio et al.   ALLERGY

Efficacy of imatinib mesylate in a case of Churg-Strauss syndrome: evidence for the pathogenic role of a tyrosine kinase?

(2013) L. Josselin-Mahr et al.   RHEUMATOLOGY

Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)

(2013) Jens Thiel et al.   ARTHRITIS RESEARCH & THERAPY

2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides

(2012) J. C. Jennette et al.   ARTHRITIS AND RHEUMATISM

Identification of JAK2 as a Mediator of FIP1L1-PDGFRA-Induced Eosinophil Growth and Function in CEL

(2012) Bin Li et al.   PLoS One

Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 production

(2008) R. J. Pepper et al.   RHEUMATOLOGY